Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Two protein modification systems — arginine methylation and ubiquitination — don't just work in parallel; they actively regulate each other, and that interplay is deeply tied to cancer. A new review in Genes & Diseases maps out this bidirectional network and its role in tumor growth, drug resistance, and immune escape. The findings point toward promising new therapeutic targets, including dual-function inhibitors and combination immunotherapy strategies.
Two major protein modification systems — arginine methylation (driven by PRMT enzymes) and ubiquitination — have long been studied separately, but a new review in Genes & Diseases reveals they form a tightly interconnected, bidirectional network with major implications for cancer biology. Rather than operating in silos, these systems constantly influence each other: methylation can shield proteins from degradation by blocking ubiquitin signals, while ubiquitination can in turn regulate the stability of the very PRMT enzymes driving methylation.
This molecular crosstalk touches nearly every hallmark of cancer — from tumor invasion and metastasis to drug resistance, immune escape, DNA repair, and metabolic reprogramming. By controlling whether key cancer-related proteins are stabilized or destroyed, the network acts as a master regulator of how cancer cells grow, survive, and respond to treatment.
Key Takeaways:
Why it matters: Understanding this crosstalk opens new doors for tackling treatment-resistant cancers. Therapies that target both pathways simultaneously could overcome limitations of current single-target approaches — though the context-dependent nature of the network means precision will be key.
